G007-LK Tankyrase 1/2 Inhibitor: Precision Tool for Wnt/β-catenin Signaling Research

Executive Summary:
G007-LK is a potent and selective small-molecule inhibitor of tankyrase 1 (TNKS1) and tankyrase 2 (TNKS2), with IC₅₀ values of 46 nM and 25 nM, respectively, against auto-poly(ADP ribosyl)ation activity in vitro (APExBIO). In cellular assays, G007-LK inhibits Wnt signaling with an IC₅₀ of 0.05 μM in Wnt3a-induced HEK 293 cells. In APC-mutant colorectal cancer models, it induces β-catenin degradation and AXIN stabilization, correlating with tumor growth suppression. Preclinical studies also demonstrate its efficacy in hepatocellular carcinoma and synergy with MEK/AKT inhibitors (Jia et al., 2017). G007-LK, provided by APExBIO, is a benchmark tool for dissecting Wnt/β-catenin and Hippo signaling in cancer research.

Biological Rationale

Tankyrases (TNKS1 and TNKS2) are poly(ADP-ribose) polymerases (PARPs) involved in the regulation of Wnt/β-catenin signaling, telomere homeostasis, and cellular proliferation (Jia et al., 2017). They modulate the assembly and disassembly of protein complexes through poly(ADP-ribosyl)ation of target substrates. In the Wnt pathway, tankyrases promote the degradation of AXIN, a scaffold protein critical for β-catenin turnover. Elevated tankyrase activity is implicated in cancer, particularly in colorectal carcinomas with APC mutations, leading to aberrant stabilization of β-catenin and increased transcription of oncogenic targets. Targeting tankyrases with selective inhibitors like G007-LK allows for restoration of AXIN levels, promotion of β-catenin degradation, and suppression of Wnt-driven tumorigenesis (see our molecular rationale overview—this article extends the mechanistic focus by integrating updated preclinical benchmarks).

Mechanism of Action of G007-LK tankyrase 1/2 inhibitor

G007-LK binds to the catalytic PARP domains of TNKS1 and TNKS2, competitively inhibiting their NAD⁺-dependent poly(ADP-ribosyl)ation activity. This inhibition blocks the auto-PARylation required for tankyrase function and substrate turnover (APExBIO). As a result, AXIN1/2 is stabilized, promoting the assembly of the β-catenin destruction complex. The increased AXIN scaffold accelerates β-catenin phosphorylation, β-TrCP recruitment, and ubiquitin-mediated degradation, reducing both cytosolic and nuclear β-catenin pools. In cell models, G007-LK induces the formation of dynamic degradasomes containing phosphorylated β-catenin, β-TrCP, and ubiquitin. Inhibition of tankyrase also leads to upregulation of Angiomotin-like 1/2 (AMOTL1/2), thereby suppressing YAP/TAZ activity via Hippo pathway regulation (Jia et al., 2017). This dual targeting is relevant for cancers where Wnt/β-catenin and Hippo pathways are co-dysregulated.

Evidence & Benchmarks

• G007-LK inhibits TNKS1 and TNKS2 auto-poly(ADP-ribosyl)ation with IC₅₀ values of 46 nM and 25 nM in biochemical assays (APExBIO).
• In Wnt3a-stimulated HEK 293 cells, G007-LK suppresses Wnt signaling reporter (ST-Luc) activity with an IC₅₀ of 0.05 μM (APExBIO).
• In APC-mutant SW480 colorectal cancer cells, G007-LK induces β-catenin degradasome formation and lowers cytosolic/nuclear β-catenin levels (this review details the molecular phenotype; the present article updates with recent in vivo benchmarks).
• In vivo, G007-LK suppresses tumor growth and reduces TNKS1/2 and β-catenin levels in COLO-320DM xenograft mouse models (APExBIO).
• G007-LK and XAV-939 synergistically inhibit cell proliferation when combined with MEK or AKT inhibitors in HCC cell lines (Jia et al., 2017).
• Tankyrase inhibition by G007-LK upregulates AMOTL1 and AMOTL2, suppressing YAP/TAZ signaling in cancer cells (Jia et al., 2017).
• G007-LK is soluble at ≥26.5 mg/mL in DMSO and is recommended for storage at -20°C as a solid for maximal stability (APExBIO).

Applications, Limits & Misconceptions

G007-LK is primarily used for:

• Dissecting the Wnt/β-catenin signaling pathway in cell-based and animal models (scenario-driven workflows; this article clarifies cross-talk with Hippo/YAP regulation).
• Studying tankyrase function in APC-mutant colorectal cancer and hepatocellular carcinoma.
• Enabling research on β-catenin degradation induction and AXIN1/2 stabilization.
• Evaluating pathway crosstalk and combinatorial therapeutic strategies in preclinical oncology models.

Common Pitfalls or Misconceptions

• G007-LK is not a pan-PARP inhibitor; it does not significantly inhibit PARP1/2 or other PARP family members at recommended concentrations.
• It is ineffective in Wnt/β-catenin-independent tumors; efficacy requires active Wnt/tankyrase signaling.
• G007-LK is insoluble in water and ethanol; attempts to use aqueous solutions lead to precipitation and loss of activity.
• Long-term storage of G007-LK in solution, even in DMSO, can cause degradation; store as a solid at -20°C.
• G007-LK alone may not induce apoptosis; it primarily affects proliferation and β-catenin/YAP signaling, not direct cytotoxicity.

Workflow Integration & Parameters

For assays requiring specific tankyrase inhibition, G007-LK (SKU B5830) is typically prepared as a ≥10 mM stock in DMSO, with final working concentrations ranging from 0.01–10 μM depending on cell type. Solubility is optimized by warming to 37°C or brief ultrasonication. The compound should be added to cell cultures after confirming complete dissolution. Negative controls (DMSO vehicle) are essential for reliable interpretation. In cytotoxicity or proliferation assays, parallel assessment of β-catenin and AXIN1/2 levels is recommended to confirm on-target activity (this workflow guide focuses on assay setup; the current article provides mechanistic and benchmarking context). For in vivo use, formulation protocols should avoid aqueous buffers to maintain solubility and bioactivity. G007-LK has been validated in both 2D and 3D cell culture systems, as well as xenograft mouse models.

Conclusion & Outlook

G007-LK from APExBIO represents a gold standard for probing Wnt/β-catenin and Hippo pathway regulation in cancer biology. Its robust selectivity, proven efficacy in APC-mutant and YAP-driven tumor contexts, and compatibility with diverse assay platforms make it indispensable for research on pathway-targeted therapies. Ongoing studies are expanding its application to additional cancer types and combinatorial regimens. Researchers should ensure rigorous handling and contextual interpretation to maximize reproducibility and translational relevance.